A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 10.1 EUR Market Closed
Market Cap: 85.9m EUR
Have any thoughts about
Apontis Pharma AG?
Write Note

Wall Street
Price Targets

APPH Price Targets Summary
Apontis Pharma AG

Wall Street analysts forecast APPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for APPH is 13.52 EUR with a low forecast of 10.1 EUR and a high forecast of 17.85 EUR.

Lowest
Price Target
10.1 EUR
0% Upside
Average
Price Target
13.52 EUR
34% Upside
Highest
Price Target
17.85 EUR
77% Upside
Apontis Pharma AG Competitors:
Price Targets
PLTH
Planet 13 Holdings Inc
184% Upside
SNDL
Sundial Growers Inc
78% Upside
SNT
Syntara Ltd
97% Upside
MEGA
Mega Lifesciences PCL
30% Upside
GLENMARK
Glenmark Pharmaceuticals Ltd
6% Upside
CONCORDBIO
Concord Biotech Ltd
5% Downside
FUM
Futura Medical PLC
332% Upside

Revenue
Forecast

Revenue Estimate
Apontis Pharma AG

For the last 3 years the compound annual growth rate for Apontis Pharma AG's revenue is -2%. The projected CAGR for the next 4 years is 22%.

-2%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Apontis Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-20%
Average Miss

Net Income
Forecast

Net Income Estimate
Apontis Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is APPH's stock price target?
Price Target
13.52 EUR

According to Wall Street analysts, the average 1-year price target for APPH is 13.52 EUR with a low forecast of 10.1 EUR and a high forecast of 17.85 EUR.

What is Apontis Pharma AG's Revenue forecast?
Projected CAGR
22%

For the last 3 years the compound annual growth rate for Apontis Pharma AG's revenue is -2%. The projected CAGR for the next 4 years is 22%.

Back to Top